STOCK TITAN

[144] Insmed, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) – Form 4 filing, 21 Jul 2025. Sr. VP, General Counsel & Secretary Meredith W. Cook reported a tax-related share withholding transaction on 18 Jul 2025.

  • Transaction type: Code F (shares withheld to satisfy taxes on vested restricted stock).
  • Securities affected: 2,071 common shares at an implied price of $66.30, total ≈ $0.14 million.
  • Post-transaction holding: Cook now directly owns 76,874 common shares.
  • Derivative positions: No derivative transactions reported; prior option/RSU holdings unchanged.

The filing reflects routine tax withholding rather than an open-market sale. Cook retains >97% of her pre-vesting equity stake, signalling continued alignment with shareholders. No impact on the company’s operations, earnings outlook or governance structure was disclosed.

ANI Pharmaceuticals (ANIP) – Deposito Form 4, 21 luglio 2025. Meredith W. Cook, Vicepresidente Senior, Consigliere Generale e Segretaria, ha segnalato una transazione di ritenuta azionaria legata a imposte il 18 luglio 2025.

  • Tipo di transazione: Codice F (azioni trattenute per soddisfare le imposte su azioni vincolate maturate).
  • Azioni interessate: 2.071 azioni ordinarie a un prezzo implicito di 66,30 $, per un totale di circa 0,14 milioni di $.
  • Detenzione post-transazione: Cook possiede ora direttamente 76.874 azioni ordinarie.
  • Posizioni derivati: Nessuna transazione derivata riportata; le precedenti posizioni in opzioni/RSU rimangono invariate.

Il deposito riflette una ritenuta fiscale di routine piuttosto che una vendita sul mercato aperto. Cook mantiene oltre il 97% della sua partecipazione azionaria pre-maturazione, indicando un continuo allineamento con gli azionisti. Non sono stati segnalati impatti sulle operazioni aziendali, sulle previsioni di guadagno o sulla struttura di governance.

ANI Pharmaceuticals (ANIP) – Presentación Formulario 4, 21 de julio de 2025. Meredith W. Cook, Vicepresidenta Senior, Asesora General y Secretaria, reportó una transacción de retención de acciones relacionada con impuestos el 18 de julio de 2025.

  • Tipo de transacción: Código F (acciones retenidas para cubrir impuestos sobre acciones restringidas adquiridas).
  • Valores afectados: 2,071 acciones comunes a un precio implícito de $66.30, total ≈ $0.14 millones.
  • Posición después de la transacción: Cook posee ahora directamente 76,874 acciones comunes.
  • Posiciones derivadas: No se reportaron transacciones derivadas; las posiciones previas en opciones/RSU permanecen sin cambios.

La presentación refleja una retención fiscal rutinaria y no una venta en el mercado abierto. Cook conserva más del 97% de su participación accionaria antes del vesting, lo que indica una alineación continua con los accionistas. No se informó impacto en las operaciones, perspectivas de ganancias o estructura de gobierno de la empresa.

ANI Pharmaceuticals (ANIP) – Form 4 제출, 2025년 7월 21일. 수석 부사장 겸 법률 고문 및 비서인 Meredith W. Cook가 2025년 7월 18일 세금 관련 주식 원천징수 거래를 보고했습니다.

  • 거래 유형: 코드 F (성숙한 제한 주식에 대한 세금 납부를 위해 주식 원천징수).
  • 영향받은 증권: 2,071 보통주, 암시 가격 $66.30, 총 약 $0.14백만.
  • 거래 후 보유: Cook는 현재 직접 76,874 보통주를 보유 중입니다.
  • 파생상품 포지션: 파생상품 거래 보고 없음; 이전 옵션/RSU 보유는 변동 없음.

이번 제출은 공개 시장 매도가 아닌 일상적인 세금 원천징수를 반영합니다. Cook는 행사 전 지분의 97% 이상을 유지하여 주주와의 지속적인 이해 일치를 나타냅니다. 회사의 운영, 수익 전망 또는 거버넌스 구조에 미치는 영향은 보고되지 않았습니다.

ANI Pharmaceuticals (ANIP) – Dépôt du Formulaire 4, 21 juillet 2025. Meredith W. Cook, Vice-Présidente Senior, Conseillère Juridique Générale et Secrétaire, a déclaré une opération de retenue d’actions liée à des impôts le 18 juillet 2025.

  • Type de transaction : Code F (actions retenues pour couvrir les impôts sur des actions restreintes acquises).
  • Titres concernés : 2 071 actions ordinaires à un prix implicite de 66,30 $, soit un total d’environ 0,14 million $.
  • Position après transaction : Cook détient désormais directement 76 874 actions ordinaires.
  • Positions sur dérivés : Aucune transaction dérivée signalée ; les positions antérieures en options/RSU restent inchangées.

Le dépôt reflète une retenue fiscale de routine plutôt qu’une vente sur le marché ouvert. Cook conserve plus de 97 % de sa participation avant acquisition, témoignant d’une alignement continu avec les actionnaires. Aucun impact sur les opérations, les perspectives de bénéfices ou la structure de gouvernance de la société n’a été communiqué.

ANI Pharmaceuticals (ANIP) – Form 4 Einreichung, 21. Juli 2025. Meredith W. Cook, Senior VP, General Counsel & Sekretärin, meldete am 18. Juli 2025 eine aktienbezogene Steuerabzugs-Transaktion.

  • Transaktionstyp: Code F (Aktien zurückbehalten zur Begleichung von Steuern auf erworbene Restricted Stock).
  • Betroffene Wertpapiere: 2.071 Stammaktien zum impliziten Preis von 66,30 $, insgesamt ca. 0,14 Mio. $.
  • Bestand nach der Transaktion: Cook hält nun direkt 76.874 Stammaktien.
  • Derivative Positionen: Keine derivativen Transaktionen gemeldet; frühere Optionen/RSU-Bestände unverändert.

Die Einreichung spiegelt eine routinemäßige Steuerabzugsmaßnahme wider, keine Veräußerung am offenen Markt. Cook behält über 97 % ihres vor der Vesting-Phase gehaltenen Aktienanteils, was auf eine weiterhin starke Ausrichtung an den Interessen der Aktionäre hinweist. Keine Auswirkungen auf den Geschäftsbetrieb, Gewinnprognosen oder die Governance-Struktur wurden bekannt gegeben.

Positive
  • Executive retains 76,874 shares, indicating continued equity exposure and alignment with shareholders.
Negative
  • 2,071 shares were disposed of (withheld for taxes), mildly increasing share float, though impact is immaterial.

Insights

TL;DR: Routine tax withholding; negligible market impact.

The Code F disposition simply covers payroll taxes on 4,820 vested RSUs. At ≈ $137k, it is immaterial relative to ANIP’s average daily dollar volume and the executive’s remaining 76.9k-share stake. Because there was no discretionary sale, the signal value is neutral. Investors should not read this as a change in insider sentiment. Impact on float and EPS is de minimis.

ANI Pharmaceuticals (ANIP) – Deposito Form 4, 21 luglio 2025. Meredith W. Cook, Vicepresidente Senior, Consigliere Generale e Segretaria, ha segnalato una transazione di ritenuta azionaria legata a imposte il 18 luglio 2025.

  • Tipo di transazione: Codice F (azioni trattenute per soddisfare le imposte su azioni vincolate maturate).
  • Azioni interessate: 2.071 azioni ordinarie a un prezzo implicito di 66,30 $, per un totale di circa 0,14 milioni di $.
  • Detenzione post-transazione: Cook possiede ora direttamente 76.874 azioni ordinarie.
  • Posizioni derivati: Nessuna transazione derivata riportata; le precedenti posizioni in opzioni/RSU rimangono invariate.

Il deposito riflette una ritenuta fiscale di routine piuttosto che una vendita sul mercato aperto. Cook mantiene oltre il 97% della sua partecipazione azionaria pre-maturazione, indicando un continuo allineamento con gli azionisti. Non sono stati segnalati impatti sulle operazioni aziendali, sulle previsioni di guadagno o sulla struttura di governance.

ANI Pharmaceuticals (ANIP) – Presentación Formulario 4, 21 de julio de 2025. Meredith W. Cook, Vicepresidenta Senior, Asesora General y Secretaria, reportó una transacción de retención de acciones relacionada con impuestos el 18 de julio de 2025.

  • Tipo de transacción: Código F (acciones retenidas para cubrir impuestos sobre acciones restringidas adquiridas).
  • Valores afectados: 2,071 acciones comunes a un precio implícito de $66.30, total ≈ $0.14 millones.
  • Posición después de la transacción: Cook posee ahora directamente 76,874 acciones comunes.
  • Posiciones derivadas: No se reportaron transacciones derivadas; las posiciones previas en opciones/RSU permanecen sin cambios.

La presentación refleja una retención fiscal rutinaria y no una venta en el mercado abierto. Cook conserva más del 97% de su participación accionaria antes del vesting, lo que indica una alineación continua con los accionistas. No se informó impacto en las operaciones, perspectivas de ganancias o estructura de gobierno de la empresa.

ANI Pharmaceuticals (ANIP) – Form 4 제출, 2025년 7월 21일. 수석 부사장 겸 법률 고문 및 비서인 Meredith W. Cook가 2025년 7월 18일 세금 관련 주식 원천징수 거래를 보고했습니다.

  • 거래 유형: 코드 F (성숙한 제한 주식에 대한 세금 납부를 위해 주식 원천징수).
  • 영향받은 증권: 2,071 보통주, 암시 가격 $66.30, 총 약 $0.14백만.
  • 거래 후 보유: Cook는 현재 직접 76,874 보통주를 보유 중입니다.
  • 파생상품 포지션: 파생상품 거래 보고 없음; 이전 옵션/RSU 보유는 변동 없음.

이번 제출은 공개 시장 매도가 아닌 일상적인 세금 원천징수를 반영합니다. Cook는 행사 전 지분의 97% 이상을 유지하여 주주와의 지속적인 이해 일치를 나타냅니다. 회사의 운영, 수익 전망 또는 거버넌스 구조에 미치는 영향은 보고되지 않았습니다.

ANI Pharmaceuticals (ANIP) – Dépôt du Formulaire 4, 21 juillet 2025. Meredith W. Cook, Vice-Présidente Senior, Conseillère Juridique Générale et Secrétaire, a déclaré une opération de retenue d’actions liée à des impôts le 18 juillet 2025.

  • Type de transaction : Code F (actions retenues pour couvrir les impôts sur des actions restreintes acquises).
  • Titres concernés : 2 071 actions ordinaires à un prix implicite de 66,30 $, soit un total d’environ 0,14 million $.
  • Position après transaction : Cook détient désormais directement 76 874 actions ordinaires.
  • Positions sur dérivés : Aucune transaction dérivée signalée ; les positions antérieures en options/RSU restent inchangées.

Le dépôt reflète une retenue fiscale de routine plutôt qu’une vente sur le marché ouvert. Cook conserve plus de 97 % de sa participation avant acquisition, témoignant d’une alignement continu avec les actionnaires. Aucun impact sur les opérations, les perspectives de bénéfices ou la structure de gouvernance de la société n’a été communiqué.

ANI Pharmaceuticals (ANIP) – Form 4 Einreichung, 21. Juli 2025. Meredith W. Cook, Senior VP, General Counsel & Sekretärin, meldete am 18. Juli 2025 eine aktienbezogene Steuerabzugs-Transaktion.

  • Transaktionstyp: Code F (Aktien zurückbehalten zur Begleichung von Steuern auf erworbene Restricted Stock).
  • Betroffene Wertpapiere: 2.071 Stammaktien zum impliziten Preis von 66,30 $, insgesamt ca. 0,14 Mio. $.
  • Bestand nach der Transaktion: Cook hält nun direkt 76.874 Stammaktien.
  • Derivative Positionen: Keine derivativen Transaktionen gemeldet; frühere Optionen/RSU-Bestände unverändert.

Die Einreichung spiegelt eine routinemäßige Steuerabzugsmaßnahme wider, keine Veräußerung am offenen Markt. Cook behält über 97 % ihres vor der Vesting-Phase gehaltenen Aktienanteils, was auf eine weiterhin starke Ausrichtung an den Interessen der Aktionäre hinweist. Keine Auswirkungen auf den Geschäftsbetrieb, Gewinnprognosen oder die Governance-Struktur wurden bekannt gegeben.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did ANIP insider Meredith Cook report in the Form 4 filed 21-Jul-2025?

She disclosed 2,071 shares of ANIP common stock were withheld on 18-Jul-2025 to pay taxes on vested RSUs.

How many ANIP shares does Meredith Cook now own?

After the transaction, she directly holds 76,874 common shares.

Was this an open-market sale of ANIP stock?

No. The Code F designation indicates shares were withheld by the company for tax purposes, not sold on the market.

Does the Form 4 affect ANIP’s earnings or guidance?

No operational or financial guidance was provided; the filing only details insider share movements.

Is the 2,071-share disposition material to ANIP shareholders?

At ≈ $137k and <0.01% of shares outstanding, the impact is not material to valuation or float.
Insmed Inc

NASDAQ:INSM

INSM Rankings

INSM Latest News

INSM Latest SEC Filings

INSM Stock Data

19.35B
187.30M
0.98%
112.55%
8.07%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER